Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets (original) (raw)

• Gilman, A. G. G proteins: transducers of receptor-generated signals. Annu. Rev. Biochem. 56, 615–649 (1987).
  CAS PubMed Google Scholar
• Oldham, W. M., Van Eps, N., Preininger, A. M., Hubbell, W. L. & Hamm, H. E. Mechanism of the receptor-catalyzed activation of heterotrimeric G proteins. Nature Struct. Mol. Biol. 9, 772–777 (2006).
  Google Scholar
• Takai, Y., Sasaki, T. & Matozaki, T. Small GTP-binding proteins. Physiol. Rev. 81, 153–208 (2001).
  CAS PubMed Google Scholar
• Etienne-Manneville, S. & Hall, A. Rho GTPases in cell biology. Nature 420, 629–635 (2002).
  CAS PubMed Google Scholar
• Pfeffer, S. & Aivazian, D. Targeting Rab GTPases to distinct membrane compartments. Nature Rev. Mol. Cell Biol. 5, 886–896 (2004).
  CAS Google Scholar
• Rocks, O., Peyker, A. & Bastiaens, P. I. Spatio-temporal segregation of Ras signals: one ship, three anchors, many harbors. Curr. Opin. Cell Biol. 18, 351–357 (2006).
  CAS PubMed Google Scholar
• Quimby, B. B. & Dasso, M. The small GTPase Ran: nterpreting the signs. Curr. Opin, Cell Biol. 15, 338–344 (2003).
  CAS Google Scholar
• D'Souza-Schorey, C. & Chavrier, P. ARF proteins: roles in membrane traffic and beyond. Nature Rev. Mol. Cell Biol. 7, 347–358 (2006).
  CAS Google Scholar
• Manser, E. Small GTPases take the stage. Dev. Cell 3, 323–328 (2002).
  CAS PubMed Google Scholar
• Bernards, A. GAPs galore! A survey of putative Ras superfamily GTPase activating proteins in man and Drosophila. Biochim. Biophys. Acta 1603, 47–82 (2003).
  CAS PubMed Google Scholar
• Rossman K. L., Der C. J. & Sondek J. GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. Nature Rev. Mol. Cell Biol. 6, 167–180 (2005).
  CAS Google Scholar
• DerMardirossian, C. & Bokoch, G. M. GDIs: central regulatory molecules in Rho GTPase activation. Trends Cell Biol. 15, 356–363 (2005).
  CAS PubMed Google Scholar
• Radhika, V. & Dhanasekaran, N. Transforming G proteins. Oncogene 20, 1607–1614 (2001).
  CAS PubMed Google Scholar
• Shaw, R. J. & Cantley, L. C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441, 424–430 (2006).
  CAS PubMed Google Scholar
• Bos, J. L. Ras oncogenes in human cancer: a review. Cancer Res. 49, 4682–4689 (1989).
  CAS PubMed Google Scholar
• Downward, J. Targeting RAS signalling pathways in cancer therapy. Nature Rev. Cancer 3, 11–22 (2003).
  CAS Google Scholar
• Daub, H., Specht, K. & Ullrich, A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nature Rev. Drug Discov. 3, 1001–1110 (2004).
  CAS Google Scholar
• Sahai, E. & Marshall, C. J. RHO-GTPases and cancer. Nature Rev. Cancer 2, 133–142 (2002).
  Google Scholar
• Preudhomme, C. Non-random 4p13 rearrangements of the RhoH/TTF gene, encoding a GTP-binding protein, in non-Hodgkin's lymphoma and multiple myeloma. Oncogene 19, 2023–2032 (2000).
  CAS PubMed Google Scholar
• Pasqualucci, L. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 412, 341–346 (2001).
  CAS PubMed Google Scholar
• Ridley, A. J. Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking. Trends Cell Biol. 16, 522–529 (2006).
  CAS PubMed Google Scholar
• Kleer, C. G. et al. RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast. Breast Cancer Res. Treat. 93, 101–110 (2005).
  CAS PubMed Google Scholar
• Kamai, T. et al. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin. Cancer Res. 9, 2632–2641 (2003).
  CAS PubMed Google Scholar
• Fidyk, N., Wang, J. B. & Cerione, R. A. Influencing cellular transformation by modulating the rates of GTP hydrolysis by Cdc42. Biochemistry 45, 7750–7762 (2006).
  CAS PubMed Google Scholar
• Lin, R., Cerione, R. A. & Manor, D. Specific contributions of the small GTPases Rho, Rac, and Cdc42 to Dbl transformation. J. Biol. Chem. 274, 23633–23641 (1999).
  CAS PubMed Google Scholar
• Cheng, K. W. et al. The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nature Med. 10, 1251–1256 (2004).
  CAS PubMed Google Scholar
• Croizet-Berger, K., Daumerie, C., Couvreur, M., Courtoy, P. J. & van den Hove, M. F. The endocytic catalysts, Rab5a and Rab7, are tandem regulators of thyroid hormone production. Proc. Natl Acad. Sci. USA 99, 8277–8282 (2002).
  CAS PubMed PubMed Central Google Scholar
• He, H. et al. Identification and characterization of nine novel human small GTPases showing variable expressions in liver cancer tissues. Gene Expr. 10, 231–242 (2002).
  CAS PubMed Google Scholar
• Hashimoto, S. et al. Requirement for ARF6 in breast cancer invasive activities. Proc. Natl Acad. Sci. USA. 101, 6647–6645 (2004).
  CAS PubMed PubMed Central Google Scholar
• Calin, G. A. et al. Familial cancer associated with a polymorphism in ARLTS1. N Engl J Med. 352, 1667–76 (2005).
  CAS PubMed Google Scholar
• Zhang, F. L. & Casey, P. J. Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65, 241–269 (1996).
  CAS PubMed Google Scholar
• Reid, T. S., Terry, K. L., Casey, P. J. & Beese L. S. Crystallographic analysis of CAAX prenyltransferases complexed with substrates defines rules of protein substrate selectivity. J. Mol. Biol. 343, 417–433 (2004).
  CAS PubMed Google Scholar
• Ashby, M. N. CaaX converting enzymes. Curr. Opin Lipidol. 9, 99–102 (1998).
  CAS PubMed Google Scholar
• Hancock, J. F., Magee, A. I., Childs, J. E. & Marshall, C. J. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 57, 1167–1177 (1989).
  CAS PubMed Google Scholar
• Hoffman, G. R., Nassar, N. & Cerione, R. A. Structure of the Rho family GTP-binding protein Cdc42 in complex with the multifunctional regulator RhoGDI. Cell 100, 345–356 (2000).
  CAS PubMed Google Scholar
• McTaggart, S. J. Isoprenylated proteins. Cell Mol. Life Sci. 63, 255–267 (2006).
  CAS PubMed Google Scholar
• Amor, J. C., Harrison, D. H., Kahn, R. A. & Ringe, D. Structure of the human ADP-ribosylation factor 1 complexed with GDP. Nature 372, 704–708 (1994).
  CAS PubMed Google Scholar
• Donovan, S., Shannon, K. M. & Bollag, G. GTPase activating proteins: critical regulators of intracellular signaling. Biochim. Biophys. Acta 1602, 23–45 (2002).
  CAS PubMed Google Scholar
• Weiss, B., Bollag, G. & Shannon, K. Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. Am. J. Med. Genet. 89, 14–22 (1999).
  CAS PubMed Google Scholar
• Crino, P. B., Nathanson, K. L. & Henske, E. P. The tuberous sclerosis complex. N. Engl. J. Med. 355, 1345–1355 (2006). An excellent review on the role of RHEB/mTOR in the pathogenesis of tuberous sclerosis.
  CAS PubMed Google Scholar
• Dransart, E., Olofsson, B. & Cherfils, J. RhoGDIs revisited: novel roles in Rho regulation. Traffic 6, 957–966 (2005).
  CAS PubMed Google Scholar
• Ivetic, A. & Ridley, A. J. Ezrin/radixin/moesin proteins and Rho GTPase signalling in leucocytes. Immunology 112, 165–176 (2004).
  CAS PubMed PubMed Central Google Scholar
• Maeda, M., Matsui, T., Imamura, M., Tsukita, S. & Tsukita, S. Expression level, subcellular distribution and rho-GDI binding affinity of merlin in comparison with Ezrin/Radixin/Moesin proteins. Oncogene 18, 4788–4797 (1999).
  CAS PubMed Google Scholar
• Kourlas, P. J. et al. Identification of a gene at 11q23 encoding a guanine nucleotide exchange factor: evidence for its fusion with MLL in acute myeloid leukemia. Proc. Natl Acad. Sci. USA 97, 2145–2150 (2000).
  CAS PubMed PubMed Central Google Scholar
• Kin, Y., Li, G, Shibuya, M. & Maru, Y. The Dbl homology domain of BCR is not a simple spacer in P210BCR-ABL of the Philadelphia chromosome. J. Biol. Chem. 276, 39462–39468 (2001).
  CAS PubMed Google Scholar
• Engers, R. et al. TIAM1 mutations in human renal-cell carcinomas. Int. J. Cancer 88, 369–376 (2000).
  CAS PubMed Google Scholar
• Wolf, R. M. et al. p190RhoGAP can act to inhibit PDGF-induced gliomas in mice: a putative tumor suppressor encoded on human chromosome 19q13.3. Genes Dev. 17, 476–487 (2003).
  CAS PubMed PubMed Central Google Scholar
• Peck, J., Douglas, G., Wu, C. H. & Burbelo, P. D. Human RhoGAP domain-containing proteins: structure, function and evolutionary relationships. FEBS Lett. 528, 27–34 (2002).
  CAS PubMed Google Scholar
• Leung T. H. et al. Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity. Proc. Natl Acad. Sci. USA 102, 15207–15212 (2005).
  CAS PubMed PubMed Central Google Scholar
• MacKeigan, J. P. et al. Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: identification of RS/DJ-1 and RhoGDIα. Cancer Res. 63, 6928–6934 (2003).
  CAS PubMed Google Scholar
• Tapper, J. et al. Changes in gene expression during progression of ovarian carcinoma. Cancer Genet. Cytogenet. 128, 1–6 (2001).
  CAS PubMed Google Scholar
• Jiang, W. G. et al. Prognostic value of rho GTPases and rho guanine nucleotide dissociation inhibitors in human breast cancers. Clin. Cancer Res. 9, 6432–6440 (2003).
  CAS PubMed Google Scholar
• Stein, M. P., Dong, J. & Wandinger-Ness, A. Rab proteins and endocytic trafficking: potential targets for therapeutic intervention. Adv. Drug Deliv. Rev. 55, 1421–1437 (2003).
  CAS PubMed Google Scholar
• Randazzo, P. A. & Hirsch, D. S. Arf GAPs: multifunctional proteins that regulate membrane traffic and actin remodelling. Cell Signal. 16, 401–413 (2004).
  CAS PubMed Google Scholar
• Demierre, M. F., Higgins, P. D., Gruber, S. B., Hawk, E. & Lippman, S. M. Statins and cancer prevention. Nature Rev. Cancer 5, 930–942 (2005).
  CAS Google Scholar
• Mo, H. & Elson, C. E. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp. Biol. Med. (Maywood) 229, 567–585 (2004).
  CAS Google Scholar
• Wong, W. W., Dimitroulakos, J., Minden, M. D. & Penn, L. Z. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16, 508–511 (2002).
  CAS PubMed Google Scholar
• Weitz-Schmidt, G. et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nature Med. 7, 687–692 (2001).
  CAS PubMed Google Scholar
• Rao, S. et al. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc. Natl Acad. Sci. USA. 96, 7797–7802 (1999).
  CAS PubMed PubMed Central Google Scholar
• Hindler, K. et al. The role of statins in cancer therapy. Oncologist 11, 306–315 (2006). An overview of the clinical trials evaluating the activity of statins as anticancer agents.
  CAS PubMed Google Scholar
• Kawata, S. et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br. J. Cancer 84, 886–891 (2001).
  CAS PubMed PubMed Central Google Scholar
• van Beek, E. et al. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem. Biophys. Res Commun. 255, 491–494 (1999).
  CAS PubMed Google Scholar
• Santini, D. et al. Mechanisms of disease: preclinical reports of antineoplastic synergistic action of bisphosphonates. Nature Clin. Pract. Oncol. 3, 325–338 (2006).
  CAS Google Scholar
• Alakangas, A. et al. Alendronate disturbs vesicular trafficking in osteoclasts. Calcif. Tissue Int. 70, 40–47 (2002).
  CAS PubMed Google Scholar
• Caraglia, M. et al. Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr. Relat. Cancer 13, 7–26 (2006).
  CAS PubMed Google Scholar
• Coxon, F. P. et al. Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo. Bone 37, 349–358 (2005).
  CAS PubMed Google Scholar
• Basso, A. D., Kirschmeier, P. & Bishop, W. R. Lipid post-translational modifications. Farnesyl transferase inhibitors. J. Lipid Res. 47, 15–31 (2006).
  CAS PubMed Google Scholar
• Kohl, N. E. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 260, 1934–1937 (1993).
  CAS PubMed Google Scholar
• Law, B. K., Norgaard, P. & Moses, H. L. Farnesyltransferase inhibitor induces rapid growth arrest and blocks p70s6k activation by multiple stimuli. J. Biol. Chem. 275, 10796–10801 (2000).
  CAS PubMed Google Scholar
• Whyte, D. B. et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem. 272, 14459–14464 (1997).
  CAS PubMed Google Scholar
• Lebowitz, P. F., Casey, P. J., Prendergast, G. C. & Thissen, J. A. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. J. Biol. Chem. 272, 15591–15594 (1997).
  CAS PubMed Google Scholar
• Du, W., Lebowitz, P. F. & Prendergast, G. C. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol. Cell Biol. 19, 1831–1840 (1999). One of the most important studies that demonstrate that geranylgeranylated RHOB has antigrowth properties, while farnesylated RHOB can be tumorigenic.
  CAS PubMed PubMed Central Google Scholar
• Chen, Z. et al. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumour growth in nude mice. J. Biol. Chem. 275, 17974–17978 (2000).
  CAS PubMed Google Scholar
• Basso, A. D. et al. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. J. Biol. Chem. 280, 31101–31108 (2005).
  CAS PubMed Google Scholar
• Tabancay, A. P. et al. Identification of dominant negative mutants of Rheb GTPase and their use to implicate the involvement of human Rheb in the activation of p70S6K. J. Biol. Chem. 278, 39921–39930 (2003).
  CAS PubMed Google Scholar
• Lackner, M. R. et al. Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors. Cancer Cell 7, 325–336 (2005).
  CAS PubMed Google Scholar
• Appels, N. M., Beijnen, J. H. & Schellens, J. H. Development of farnesyl transferase inhibitors: a review. Oncologist 10, 565–578 (2005).
  PubMed Google Scholar
• Adjei, A. A., Davis, J. N., Erlichman, C., Svingen, P. A. & Kaufmann, S. H. Comparison of potential markers of farnesyltransferase inhibition. Clin. Cancer Res. 6, 2318–2325 (2000). A useful discussion of potential biomarkers of FTase inhibition.
  CAS PubMed Google Scholar
• Van Cutsem, E. et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol. 22, 1430–1438 (2004).
  CAS PubMed Google Scholar
• Rao, S. et al. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J. Clin. Oncol. 22, 3950–3957 (2004).
  CAS PubMed Google Scholar
• McDonald, J. S. et al. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest Oncology Group (SWOG 9924) study. Invest. New Drugs 23, 485–487 (2005).
  Google Scholar
• Zimmerman, T. M. et al. Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J. Clin. Oncol. 22, 4816–4822 (2004).
  CAS PubMed Google Scholar
• Lancet, J. E. et al. A Phase II study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood 109, 1387–1394 (2007).
  CAS PubMed PubMed Central Google Scholar
• Caraglia, M., Budillon, A., Tagliaferri, P., Marra, M., Abbruzzese, A. & Caponigro, F. Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications. Curr. Drug Targets 6, 301–323 (2005).
  CAS PubMed Google Scholar
• Di Paolo, A. et al. Inhibition of protein farnesylation enhances the chemotherapeutic efficacy of the novel geranylgeranyltransferase inhibitor BAL9611 in human colon cancer cells. Br. J. Cancer. 84, 1535–1543 (2001).
  CAS PubMed Google Scholar
• Lobell, R. B. et al. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res. 61, 8758–8768 (2001).
  CAS PubMed Google Scholar
• Morgan, M. A., Wegner, J., Aydilek, E., Ganser, A. & Reuter, C. W. Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors. Leukemia 17, 1508–1520 (2003).
  CAS PubMed Google Scholar
• Reid, T. S. et al. Crystallographic analysis reveals that anticancer clinical candidate L-778,123 inhibits protein farnesyltransferase and geranygeranyltransferase-I by different binding modes. Biochemistry 43, 9000–9008 (2004).
  CAS PubMed Google Scholar
• Lobell, R. B. et al. Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl: protein transferase type-I. Mol. Cancer Ther. 1, 747–758 (2002).
  CAS PubMed Google Scholar
• Kelly, J. et al. The prenyltransferase inhibitor AZD3409 has anti-tumour activity in preclinical models of urothelial carcinoma. Proc. Am. Assoc. Cancer Res. 46, 5962 (2005).
  Google Scholar
• Bergo, M. O. et al. Absence of the CAAX endoprotease RCE1: effects on cell growth and transformation. Mol. Cell Biol. 22, 171–181 (2002).
  CAS PubMed PubMed Central Google Scholar
• Bergo, M. O. et al. Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf. J. Clin. Invest. 113, 539–550 (2004). A pivotal paper showing that the inhibition of ICMT activity blocks oncogenic KRAS-induced transformation by decreasing the methylation of KRAS, HRAS and NRAS.
  CAS PubMed PubMed Central Google Scholar
• Winter-Vann, A. M. & Casey, P. J. Post-prenylation-processing enzymes as new targets in oncogenesis. Nature Rev. Cancer. 5, 405–412 (2005).
  CAS Google Scholar
• Schlitzer, M., Winter-Vann, A. & Casey, P. J. Non-peptidic, non-prenylic inhibitors of the prenyl protein-specific protease Rce1. Bioorg. Med. Chem. Lett. 11, 425–427 (2001).
  CAS PubMed Google Scholar
• Chen, Y. Selective inhibition of ras-transformed cell growth by a novel fatty acid-based chloromethyl ketone designed to target Ras endoprotease. Ann. NY Acad. Sci. 886, 103–108 (1999).
  CAS PubMed Google Scholar
• Wnuk, S. F. et al. Anticancer and antiviral effects and inactivation of _S_-adenosyl-L-homocysteine hydrolase with 5′-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues. J. Med. Chem. 40, 1608–1618 (1997).
  CAS PubMed Google Scholar
• Winter-Vann, A. M. et al. Targeting Ras signaling through inhibition of carboxyl methylation: an unexpected property of methotrexate. Proc. Natl Acad. Sci. USA 100, 6529–6534 (2003).
  CAS PubMed PubMed Central Google Scholar
• Winter-Vann, A. M. et al. A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells. Proc. Natl Acad. Sci. USA 102, 4336–4341 (2005).
  CAS PubMed PubMed Central Google Scholar
• Michaelson, D. et al. Postprenylation CAAX processing is required for proper localization of Ras but not Rho GTPases. Mol. Biol. Cell 16, 1606–1616 (2005).
  CAS PubMed PubMed Central Google Scholar
• Kramer, K., et al. Isoprenylcysteine carboxyl methyltransferase activity modulates endothelial cell apoptosis. Mol. Biol. Cell 14, 848–857 (2003).
  CAS PubMed PubMed Central Google Scholar
• Chiu, V. K. et al. Ras signalling on the endoplasmic reticulum and the Golgi. Nature Cell Biol. 4, 343–350 (2002). An important study that provides evidence that mislocalized farnesylated or geranylgeranylated RAS (specifically NRAS and HRAS) can still signal from other locations besides the plasma membrane.
  CAS PubMed Google Scholar
• Leow, J. L., Baron, R., Casey, P. J. & Go, M. L. Quantitative structure–activity relationship (QSAR) of indoloacetamides as inhibitors of human isoprenylcysteine carboxyl methyltransferase. Bioorg. Med. Chem. Lett. 17, 1025–1032 (2006).
  PubMed PubMed Central Google Scholar
• Roberts, M. J. et al. Hydrophilic anilinogeranyl diphosphate prenyl analogues are ras function inhibitors. Biochemistry 45, 15862–15872 (2006).
  CAS PubMed Google Scholar
• Morgan, M. A. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells. Br. J. Haematol. 130, 912–925 (2005).
  CAS PubMed Google Scholar
• Mo, H. & Elson, C. E. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp. Biol. Med. (Maywood) 229, 567–585 (2004).
  CAS Google Scholar
• Elson, C. E. et al. Isoprenoid-mediated inhibition of mevalonate synthesis: potential application to cancer. Proc. Soc. Exp. Biol. Med. 221, 294–311 (1999).
  CAS PubMed Google Scholar
• Andela, V. B. Synergism of aminobisphosphonates and farnesyl transferase inhibitors on tumour metastasis. Clin. Orthop. Relat. Res. 397, 228–239 (2002).
  Google Scholar
• Budman, D. R. & Calabro, A. Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents. Oncology 70, 147–153 (2006).
  CAS PubMed Google Scholar
• Hoover, R. R., Mahon, F. X., Melo, J. V. & Daley, G. Q. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 100, 1068–1071 (2002).
  CAS PubMed Google Scholar
• Jorgensen, H. G. et al. Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro. Leukemia 19, 1184–1191 (2005).
  CAS PubMed Google Scholar
• Moasser, M. M. et al. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc. Natl Acad. Sci. USA 95, 1369–1374 (1998).
  CAS PubMed PubMed Central Google Scholar
• Shi, B. et al. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumour activity in vivo. Cancer Chemother. Pharmacol. 46, 387–393 (2000).
  CAS PubMed Google Scholar
• Marcus, A. I. et al. Farnesyltransferase inhibitors reverse taxane resistance. Cancer Res. 66, 8838–8846 (2006).
  CAS PubMed PubMed Central Google Scholar
• Adjei, A. A., Davis, J. N., Bruzek, L. M., Erlichman, C. & Kaufmann, S. H. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin. Cancer Res. 7, 1438–1445 (2001).
  CAS PubMed Google Scholar
• Doisneau-Sixou, S. F., Cestac, P., Faye, J. C., Favre, G., Sutherland, R. L. Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-cycle progression. Int. J. Cancer 106: 789–798 (2003).
  CAS PubMed Google Scholar
• Edamatsu, H., Gau, C. L., Nemoto, T., Guo, L., & Tamanoi, F. Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines. Oncogene 19, 3059–3068 (2000).
  CAS PubMed Google Scholar
• Russo, P., Malacarne, D., Falugi, C., Trombino, S. & O'Connor, P. M. RPR-115135, a farnesyltransferase inhibitor, increases 5-FU cytotoxicity in ten human colon cancer cell lines: role of p53. Int. J. Cancer 100, 266–275 (2002).
  CAS PubMed Google Scholar
• Neville-Webbe, H. L., Evans, C. A., Coleman, R. E. & Holen, I. Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol. 27, 92–103 (2006).
  CAS PubMed Google Scholar
• Ullen, A. et al. Additive/synergistic antitumoural effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncol. 44, 644–650 (2005).
  CAS PubMed Google Scholar
• Melisi, D. et al. Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. Endocr. Relat. Cancer 12, 1051–1058 (2005).
  CAS PubMed Google Scholar
• Segawa, H. et al. Zoledronate synergises with imatinib mesylate to inhibit Ph primary leukaemic cell growth. Br. J. Haematol. 130, 558–560 (2005).
  CAS PubMed Google Scholar
• Brunner, T. B., Hahn, S. M., McKenna, W. G. & Bernhard, E. J. Radiation sensitization by inhibition of activated Ras. Strahlenther Onkol. 180, 731–740 (2004).
  PubMed Google Scholar
• Brunner, T. B. et al. Farnesyltransferase inhibitors as radiation sensitizers. Int. J. Radiat. Biol. 79, 569–576 (2003).
  CAS PubMed Google Scholar
• Martin, N. E. et al. A Phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer. Clin. Cancer Res. 10, 5447–5454 (2004).
  CAS PubMed Google Scholar
• Onodera, Y. et al. Expression of AMAP1, an ArfGAP, provides novel targets to inhibit breast cancer invasive activities. EMBO J. 24, 963–973 (2005)
  CAS PubMed PubMed Central Google Scholar
• Tesmer, J. J. Hitting the hot spots of cell signaling cascades. Science. 312, 377–378 (2006). An excellent review that discusses the concept of interfacial inhibition and its potential as a strategy for drug discovery.
  CAS PubMed Google Scholar
• Pommier, Y. & Cherfils, J. Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discovery. Trends Pharmacol. Sci. 26, 138–145 (2005).
  CAS PubMed Google Scholar
• Zeghouf, M., Guibert, B., Zeeh, J. C. & Cherfils, J. Arf, Sec7 and Brefeldin A: a model towards the therapeutic inhibition of guanine nucleotide-exchange factors. Biochem. Soc. Trans. 33, 1265–1268 (2005).
  CAS PubMed Google Scholar
• Zeeh, J. et al. Dual specificity of the interfacial inhibitor brefeldin A for arf proteins and sec7 domains. J. Biol. Chem. 281, 11805–11814 (2006).
  CAS PubMed Google Scholar
• Gao, Y., Dickerson, J. B., Guo, F., Zheng, J. & Zheng Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc. Natl Acad. Sci. USA. 101, 7618–7622 (2004). A seminal paper describing the development of NSC23766 by a structure-based virtual screening of compounds that fit into the GEF-recognition groove centring on Trp56 of RAC1.
  CAS PubMed PubMed Central Google Scholar
• Schmidt, S., Diriong, S., Mery, J., Fabbrizio, E. & Debant, A. Identification of the first Rho GEF inhibitor, TRIPα, which targets the RhoA-specific GEF domain of Trio. FEBS Lett. 523, 35–44 (2002).
  CAS PubMed Google Scholar
• Cancelas, J. A. et al. Rac GTPases differentially integrate signals regulating hematopoietic stem cell localization. Nature Med. 11, 886–891 (2005).
  CAS PubMed Google Scholar
• Kato-Stankiewicz, J. et al. Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells. Proc. Natl Acad. Sci. USA. 99, 14398–14403 (2002).
  CAS PubMed PubMed Central Google Scholar
• Fritz, G. & Kaina, B. Rho GTPases: promising cellular targets for novel anticancer drugs. Curr. Cancer Drug Targets 6, 1–14 (2006).
  CAS PubMed Google Scholar
• Just, I. et al. Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature 375, 500–503 (1995).
  CAS PubMed Google Scholar
• Pille, J. Y. et al. Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo. Mol. Ther. 11, 267–274 (2005).
  CAS PubMed Google Scholar
• Zhang, B. Rho GDP dissociation inhibitors as potential targets for anticancer treatment. Drug Resist. Updat. 9, 134–141 (2006).
  CAS PubMed Google Scholar
• Poppe, D. et al. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J. Immunol. 176, 640–651 (2006).
  CAS PubMed Google Scholar
• Peterson, Y. K., Kelly, P., Weinbaum, C. A. & Casey, P. J. A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity. J. Biol. Chem. 281, 12445–12450 (2006). This paper highlights the development of GGTase I inhibitors (GGTIs) that demonstrate selectivity for monomeric versus heterotrimeric G proteins (such as GGTI DU40).
  CAS PubMed Google Scholar
• Lewis, K. D. et al. A Phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma. Invest. New Drugs 24, 89–94 (2006).
  CAS PubMed Google Scholar
• Kim, W. S. et al. Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest. New Drugs 19, 81–83 (2001).
  CAS PubMed Google Scholar
• Knoxx, J. J. et al. A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. Eur. J. Cancer 41, 523–530 (2005).
  Google Scholar
• van der Spek, E. et al. Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma. Haematologica 91, 542–545 (2006).
  CAS PubMed Google Scholar
• Blumenschein, G. et al. O-082. A randomized Phase III trial comparing lonafarnib/carboplatin/paclitaxel versus carboplatin/paclitaxel (CP) in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC). Lung Cancer 49 (Suppl. 2), 30 (2005).
  Google Scholar